Tag Archives: Lilly

Is There a Global Policy Gap on Cancer?

By William Looney | Published: January 30, 2013
Eli Lilly thinks so, with a new “back to school” pathway on stakeholder engagement Monday, February 4, is World Cancer Day.  Eli Lilly & Co., one of big Pharma’s biggest, has decided to give the moment its due with the launch of a new policy advocacy initiative to ensure that patients actually benefit from the [...]
Posted in Global | Also tagged , , | Leave a comment

Fixing Innovation: Lilly's CEO Says Why, and How

By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing | Also tagged , , , , , , , , , , , , | 1 Comment

CETP Inhibitors: Blockbusters that Never Ran?

By Ben Comer | Published: May 7, 2012
The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts say.
Posted in Biotech, R&D, Technology, leadership | Also tagged , , , , , , | Leave a comment

Saving Haiti: One Donation at a Time (UPDATED 1/21)

By George Koroneos | Published: January 15, 2010
Image by American Red Cross via Flickr It’s been less than three days since new broke of a massive earthquake in Haiti that all but leveled the struggling country. With thousands dead, a devastated infrastructure, and no emergency plan, countries and businesses around the world have joined in the effort to help the Haitian people with [...]
Posted in News | Also tagged , , , , , , , | 2 Comments

Lilly Osteoporosis Drug Canned in Phase III Trials

By George Koroneos | Published: August 19, 2009
Image by go elsewhere… via Flickr Lilly, on Wednesday, announced that it would not seek regulatory approval for its osteoporosis treatment arzoxifene, because the drug failed to meet certain end points in Phase III clinical trials. The good news is that the drug was successful in meeting the primary end point of the trial, dubbed “GENERATIONS.” [...]
Posted in Strategy | Also tagged , , , , , | 1 Comment